Processa Pharmaceuticals Inc [PCSA] stock is trading at $0.27, up 4.57%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PCSA shares have gain 12.92% over the last week, with a monthly amount drifted -39.70%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Processa Pharmaceuticals Inc [NASDAQ: PCSA] stock has seen the most recent analyst activity on April 25, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $8.
Processa Pharmaceuticals Inc [PCSA] stock has fluctuated between $0.21 and $3.10 over the past year. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. Processa Pharmaceuticals Inc [NASDAQ: PCSA] shares were valued at $0.27 at the most recent close of the market. An investor can expect a potential return of 3233.33% based on the average PCSA price forecast.
Analyzing the PCSA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -3.67, Equity is -2.33 and Total Capital is -8.76. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.2372 points at the first support level, and at 0.2043 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.3115, and for the 2nd resistance point, it is at 0.3529.
Ratios To Look Out For
For context, Processa Pharmaceuticals Inc’s Current Ratio is 1.22. In addition, the Quick Ratio stands at 1.22 and the Cash Ratio stands at 0.78.
Transactions by insiders
Recent insider trading involved Yorke Justin W, Director, that happened on Jan 27 ’25 when 12400.0 shares were purchased. Chief Executive Officer, Ng George K completed a deal on Jan 27 ’25 to buy 87200.0 shares. Meanwhile, Pres. Research & Development Young David bought 0.12 million shares on Jan 27 ’25.
